Ocugen Earnings Call Transcripts
Fiscal Year 2026
-
Three late-stage gene therapy programs are advancing for retinitis pigmentosa, Stargardt disease, and geographic atrophy, with two BLAs planned next year and a third in 2028. Phase II/III data show strong efficacy and safety, and adaptive trial designs aim to optimize outcomes.
-
The meeting, held virtually for accessibility, included director elections, ratification of the accounting firm, and advisory votes on executive compensation and its voting frequency. All proposals passed, and a brief Q&A followed with no further questions.
-
Gene therapy programs for retinal diseases show strong efficacy, with OCU410 reducing GA lesion growth by 31% in one year and OCU400 targeting RP across 100+ mutations. Three pivotal trials are advancing globally, with major regulatory filings and potential approvals expected by 2028.
-
Three late-stage gene therapy programs are advancing for major retinal diseases, using master regulator genes to address broad patient populations and unmet needs. Rolling BLA submissions and adaptive trial designs aim for regulatory filings by 2028, supported by strong cash reserves and global market strategy.
-
Q1 2026 saw major clinical and financial milestones, including a $115M convertible notes offering, positive phase II data in GA, and completed pivotal trial enrollments. Cash runway is projected into 2028, supporting three BLA submissions by 2028.
-
The phase II ArMaDa trial of OCU410 in GA showed a 31% reduction in lesion growth and 27% slower ellipsoid zone loss at 12 months, with a favorable safety profile and no treatment-related serious adverse events. Medium dose was optimal, supporting advancement to a global phase III trial.
-
OCU410, a one-time gene therapy for geographic atrophy, showed a 46% reduction in lesion growth at 12 months in phase II, with a strong safety profile and up to 50% of patients achieving significant benefit. The therapy targets multiple disease pathways and may offer a durable alternative to chronic injections.
Fiscal Year 2025
-
Significant clinical and operational progress was made across gene therapy programs, with key trials advancing toward pivotal data and regulatory filings. Financial position was strengthened through new capital raises, supporting a cash runway into late 2026 or beyond.
-
OCU400 and OCU410ST gene therapy programs advanced toward late-stage regulatory milestones, with strong clinical progress, expanded global partnerships, and a strengthened cash position supporting operations into 2026. Manufacturing and commercialization plans are on track for 2027 launches.
-
Three gene therapy programs for major blindness diseases are advancing toward BLA filings between 2026 and 2028, with OCU400 leading in Phase 3 for retinitis pigmentosa. Early clinical data show strong safety and efficacy, and recent financial moves have extended the cash runway into 2027.
-
Advanced late-stage gene therapy programs for RP, Stargardt, and GA, with key regulatory and clinical milestones achieved. Cash position declined to $27.3M, with ongoing strategic partnerships and non-dilutive funding efforts. Top-line data and regulatory filings expected in 2026-2027.
-
Advanced gene therapy programs achieved key regulatory milestones, with pivotal trials and BLA/MAA filings on track over the next three years. R&D expenses rose, net loss widened, and cash runway extends into Q1 2026. EMA and FDA support underscores strong market potential.
Fiscal Year 2024
-
Advanced three gene therapy programs with positive clinical data and regulatory progress, secured $65M in new financing, and extended cash runway into Q1 2026. BLA filings targeted for 2026–2028, with pivotal trials and interim data expected in 2025.
-
Three gene therapy programs are advancing for inherited retinal diseases and macular degeneration, with strong safety, early efficacy, and broad patient access initiatives. Clinical data show stabilization or improvement in vision, and commercial projections highlight large market opportunities.
-
Key clinical milestones were achieved, including regulatory approvals for OCU400 and OCU200, while $30 million in new financing extended the cash runway into Q1 2026. Operating expenses declined year-over-year, and multiple gene therapy programs advanced toward pivotal data and regulatory filings.
-
The company is advancing a novel modified gene therapy platform for retinal diseases, with OCU400 in phase III for RP and LCA, and OCU410/OCU410ST in trials for geographic atrophy and Stargardt disease. Early data show broad efficacy and safety, with regulatory submissions targeted for 2026.
-
The gene therapy platform is advancing with OCU400 in phase III for RP and OCU410 in phase I/II for dry AMD and Stargardt disease, targeting broad patient populations. Regulatory progress and expanded access programs support global reach, with key data and partnership milestones expected by year-end.
-
Modifier gene therapy programs advanced, with OCU400 phase III on track for 2026 approval and FDA expanded access granted. Q2 operating expenses fell 31% year-over-year, and a $32.6M fundraising extends cash runway into Q3 2025.